安罗替尼治疗肺癌的临床研究进展
|
摘要
肺癌是目前全世界发病率及病死率均居前列的恶性肿瘤。近年来,基于驱动基因的分子靶向精准治疗彻底改变了晚期肺癌患者的治疗模式,新型抗肿瘤药物层出不穷。安罗替尼(AL3818,anlotinib)是中国自主研发的一种新型小分子多靶点酪氨酸激酶抑制剂(tyrosine kinase inhibition,TKI),其具有抗肿瘤血管生成和抑制肿瘤细胞生长的作用,且安全性较好,目前已被国家食品药品监督管理局(China Food and Drug Administration,cFDA)批准用于肺癌的三线及以上治疗。本文就安罗替尼抗肿瘤作用机制、相关临床研究、寻找预测疗效的标志物及不良反应等方面在肺癌中的研究进展作一综述。
引文
[1]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019[J].CA A Cancer J Clin,2019,69(1):7-34.DOI:10.3322/caac.21551.
[2]CHEN W Q,SUN K X,ZHENG R S,et al.Cancer incidence and mortality in China,2014[J/OL].Chin J Cancer Res,2018,30(1):1-12[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842223/.DOI:10.21147/j.issn.1000-9604.2018.01.01.
[3]RAWLUK J,WALLER C F.Gefitinib[J].Recent Results Cancer Res,2018,211:235-246.DOI:10.1007/978-3-319-91442-8_16.
[4]TAN C S,KUMARAKULASINGHE N B,HUANG Y Q,et al.Third generation EGFR TKIs:current data and future directions[J/OL].Mol Cancer,2018,17(1):29[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817792/.DOI:10.1186/s12943-018-0778-0.
[5]NISHIO M,KIM D W,WU Y L,et al.Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer[J/OL].Cancer Res Treat,2018,50(3):691-700[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/.DOI:10.4143/crt.2017.280.
[6]姜战胜,潘战宇,任秀宝.晚期非小细胞肺癌一线靶向治疗的研究进展[J].中国肿瘤生物治疗杂志,2017,24(10):1129-1133.DOI:10.3872/j.issn-1007-385x.2017.10.015.
[7]SYED Y Y.Anlotinib:first global approval[J].Drugs,2018,78(10):1057-1062.DOI:10.1007/s40265-018-0939-x.
[8]CHEN X Z.Anlotinib for refractory advanced non-small cell lung cancer in China[J].JAMA Oncol,2019,5(1):116-117.DOI:10.1001/jamaoncol.2018.5526.
[9]CHENG Y,WU Y,LU S,et al.Chinese Society of Clinical Oncology(CSCO)guidelines for diagnosis and treatment of primary lung cancer[J].Cancer Communciations,2019,39:10-14.DOI:10.1186/s40882019-0349-9.
[10]HEGDE P S,WALLIN J J,MANCAO C.Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics[J].Semin Cancer Biol,2018,52(Pt 2):117-124.DOI:10.1016/j.semcancer.2017.12.002.
[11]FREZZETTI D,GALLO M,MAIELLO M R,et al.VEGF as a potential target in lung cancer[J].Expert OpinTher Targets,2017,21(10):959-966.DOI:10.1080/14728222.2017.1371137.
[12]PAPADOPOULOS N,LENNARTSSON J.The PDGF/PDGFRpathway as a drug target[J].Mol Aspects Med,2018,62:75-88.DOI:10.1016/j.mam.2017.11.007.
[13]PRESTA M,CHIODELLI P,GIACOMINI A,et al.Fibroblast growth factors(FGFs)in cancer:FGF traps as a new therapeutic approach[J].Pharmacol Ther,2017,179:171-187.DOI:10.1016/j.pharmthera.2017.05.013.
[14]LIN B Y,SONG X M,YANG D W,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβand FGFR1[J].Gene,2018,654:77-86.DOI:10.1016/j.gene.2018.02.026.
[15]XIE C Y,WAN X Z,QUAN H T,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J].Cancer Sci,2018,109(4):1207-1219.DOI:10.1111/cas.13536.
[16]ABBASPOUR BABAEI M,KAMALIDEHGHAN B,SALEEM M,et al.Receptor tyrosine kinase(c-Kit)inhibitors:a potential therapeutic target in cancer cells[J].DDDT,2016,10:2443-2459.DOI:10.2147/dddt.s89114.
[17]CARDOSO H J,FIGUEIRA M I,CORREIA S,et al.The SCF/cKIT system in the male:Survival strategies in fertility and cancer[J].Mol Reprod Dev,2014,81(12):1064-1079.DOI:10.1002/mrd.22430.
[18]SUN Y K,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors[J/OL].JHematol Oncol,2016,9(1):105[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051080/.DOI:10.1186/s13045-016-0332-8.
[19]HAN B H,LI K,ZHAO Y Z,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomised phase II trial(ALTER0302)[J/OL].Br JCancer,2018,118(5):654-6612019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846072/.DOI:10.1038/bjc.2017.478.
[20]HAN B H,LI K,WANG Q M,et al.Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial[J/OL].JAMA Oncol,2018,4(11):1569-1575[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248083/.DOI:10.1001/jamaoncol.2018.3039.
[21]SI X Y,ZHANG L,WANG H P,et al.Quality of life results from a randomized,double-blinded,placebo-controlled,multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer[J].Lung Cancer,2018,122:32-37.DOI:10.1016/j.lungcan.2018.05.013.
[22]斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志,2018,57(11):830-834.DOI:10.3760/cma.j.issn.0578-1426.2018.11.007.
[23]苏雨栋,孟昭婷,徐晓燕,等.安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肺癌杂志,2018,21(5):428-430.DOI:10.3779/j.issn.1009-3419.2018.05.13.
[24]BAIZE N,MONNET I,GREILLIER L,et al.Second-line treatments of small-cell lung cancers[J].Expert Review of Anticancer Therapy,2017,17(11):1033-1043.DOI:10.1080/14737140.2017.1372198.
[25]TSOUKALAS N,ARAVANTINOU-FATOROU E,BAXEVANOSP,et al.Advanced small cell lung cancer(SCLC):new challenges and new expectations[J/OL].Ann Transl Med,2018,6(8):145[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952028/.DOI:10.21037/atm.2018.03.31.
[26]CHENG Y,WANG Q,LI K,et al.Anlotinib as third-line or furtherline treatment in relapsed SCLC:a multicentre,randomized,doublebl-ind phase 2 trial[J/OL].WCLC,2018,OA 13.03[2019-02-22].https://www.clinicaloptions.com/oncology/conference-coverage/wclc-2018/capsule-summary-slidesets/oa13_03.
[27]LIU Z J,WANG J,MENG Z T,et al.CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer:Analysis on ALTER-0303 study[J/OL].Cancer Med,2018,7(7):3011-3021[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051165/.DOI:10.1002/cam4.1584.
[28]HAN B,LI K,WANG Q,et al.P3.03-006 efficiency of anlotinib as3rd line treatment in patients with different EGFR gene status,an exploratory subgroup analysis of ALTER0303 trial[J].J Thoracic Oncol,2017,12(11):S2275.DOI:10.1016/j.jtho.2017.09.1632.
[29]LI K,HAN B H,WANG Q M,et al.OS outcomes to anlotinib in patients(pts)with refractory NSCLC of both wild-type(WT)and mutant EGFR[J].JCO,2018,36(15_suppl):e21013.DOI:10.1200/jco.2018.36.15_suppl.e21013.
[30]HAN B,ZHAO Y,LI K,et al.P3.03-017blood samples NGS for baseline molecular signature of anotinib treated advanced NSCLCpatients in ALTER0303 trial[J].J Thoracic Oncol,2017,12(11):S2279.DOI:10.1016/j.jtho.2017.09.1643.
[31]LU J,ZHONG H,CHU T Q,et al.Role of anlotinib-induced CCL2decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy[J].Eur Respir J,2019,53(3):1801562.DOI:10.1183/13993003.01562-2018.
[32]SI X Y,ZHANG L,WANG H P,et al.Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer:Experiences in ALTER-0303[J/OL].Thorac Cancer,2019,10(3):551-556[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397894/.DOI:10.1111/1759-7714.12977.
[33]SUN W,WANG Z,CHEN R M,et al.Influences of anlotinib on cytochrome P450 enzymes in rats using a cocktail method[J/OL].Biomed Res Int,2017,2017:3619723[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758843/.DOI:10.1155/2017/3619723.
[2]CHEN W Q,SUN K X,ZHENG R S,et al.Cancer incidence and mortality in China,2014[J/OL].Chin J Cancer Res,2018,30(1):1-12[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842223/.DOI:10.21147/j.issn.1000-9604.2018.01.01.
[3]RAWLUK J,WALLER C F.Gefitinib[J].Recent Results Cancer Res,2018,211:235-246.DOI:10.1007/978-3-319-91442-8_16.
[4]TAN C S,KUMARAKULASINGHE N B,HUANG Y Q,et al.Third generation EGFR TKIs:current data and future directions[J/OL].Mol Cancer,2018,17(1):29[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817792/.DOI:10.1186/s12943-018-0778-0.
[5]NISHIO M,KIM D W,WU Y L,et al.Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer[J/OL].Cancer Res Treat,2018,50(3):691-700[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984/.DOI:10.4143/crt.2017.280.
[6]姜战胜,潘战宇,任秀宝.晚期非小细胞肺癌一线靶向治疗的研究进展[J].中国肿瘤生物治疗杂志,2017,24(10):1129-1133.DOI:10.3872/j.issn-1007-385x.2017.10.015.
[7]SYED Y Y.Anlotinib:first global approval[J].Drugs,2018,78(10):1057-1062.DOI:10.1007/s40265-018-0939-x.
[8]CHEN X Z.Anlotinib for refractory advanced non-small cell lung cancer in China[J].JAMA Oncol,2019,5(1):116-117.DOI:10.1001/jamaoncol.2018.5526.
[9]CHENG Y,WU Y,LU S,et al.Chinese Society of Clinical Oncology(CSCO)guidelines for diagnosis and treatment of primary lung cancer[J].Cancer Communciations,2019,39:10-14.DOI:10.1186/s40882019-0349-9.
[10]HEGDE P S,WALLIN J J,MANCAO C.Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics[J].Semin Cancer Biol,2018,52(Pt 2):117-124.DOI:10.1016/j.semcancer.2017.12.002.
[11]FREZZETTI D,GALLO M,MAIELLO M R,et al.VEGF as a potential target in lung cancer[J].Expert OpinTher Targets,2017,21(10):959-966.DOI:10.1080/14728222.2017.1371137.
[12]PAPADOPOULOS N,LENNARTSSON J.The PDGF/PDGFRpathway as a drug target[J].Mol Aspects Med,2018,62:75-88.DOI:10.1016/j.mam.2017.11.007.
[13]PRESTA M,CHIODELLI P,GIACOMINI A,et al.Fibroblast growth factors(FGFs)in cancer:FGF traps as a new therapeutic approach[J].Pharmacol Ther,2017,179:171-187.DOI:10.1016/j.pharmthera.2017.05.013.
[14]LIN B Y,SONG X M,YANG D W,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβand FGFR1[J].Gene,2018,654:77-86.DOI:10.1016/j.gene.2018.02.026.
[15]XIE C Y,WAN X Z,QUAN H T,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J].Cancer Sci,2018,109(4):1207-1219.DOI:10.1111/cas.13536.
[16]ABBASPOUR BABAEI M,KAMALIDEHGHAN B,SALEEM M,et al.Receptor tyrosine kinase(c-Kit)inhibitors:a potential therapeutic target in cancer cells[J].DDDT,2016,10:2443-2459.DOI:10.2147/dddt.s89114.
[17]CARDOSO H J,FIGUEIRA M I,CORREIA S,et al.The SCF/cKIT system in the male:Survival strategies in fertility and cancer[J].Mol Reprod Dev,2014,81(12):1064-1079.DOI:10.1002/mrd.22430.
[18]SUN Y K,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors[J/OL].JHematol Oncol,2016,9(1):105[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051080/.DOI:10.1186/s13045-016-0332-8.
[19]HAN B H,LI K,ZHAO Y Z,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomised phase II trial(ALTER0302)[J/OL].Br JCancer,2018,118(5):654-6612019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846072/.DOI:10.1038/bjc.2017.478.
[20]HAN B H,LI K,WANG Q M,et al.Effect of anlotinib as a thirdline or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial[J/OL].JAMA Oncol,2018,4(11):1569-1575[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248083/.DOI:10.1001/jamaoncol.2018.3039.
[21]SI X Y,ZHANG L,WANG H P,et al.Quality of life results from a randomized,double-blinded,placebo-controlled,multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer[J].Lung Cancer,2018,122:32-37.DOI:10.1016/j.lungcan.2018.05.013.
[22]斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志,2018,57(11):830-834.DOI:10.3760/cma.j.issn.0578-1426.2018.11.007.
[23]苏雨栋,孟昭婷,徐晓燕,等.安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肺癌杂志,2018,21(5):428-430.DOI:10.3779/j.issn.1009-3419.2018.05.13.
[24]BAIZE N,MONNET I,GREILLIER L,et al.Second-line treatments of small-cell lung cancers[J].Expert Review of Anticancer Therapy,2017,17(11):1033-1043.DOI:10.1080/14737140.2017.1372198.
[25]TSOUKALAS N,ARAVANTINOU-FATOROU E,BAXEVANOSP,et al.Advanced small cell lung cancer(SCLC):new challenges and new expectations[J/OL].Ann Transl Med,2018,6(8):145[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952028/.DOI:10.21037/atm.2018.03.31.
[26]CHENG Y,WANG Q,LI K,et al.Anlotinib as third-line or furtherline treatment in relapsed SCLC:a multicentre,randomized,doublebl-ind phase 2 trial[J/OL].WCLC,2018,OA 13.03[2019-02-22].https://www.clinicaloptions.com/oncology/conference-coverage/wclc-2018/capsule-summary-slidesets/oa13_03.
[27]LIU Z J,WANG J,MENG Z T,et al.CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer:Analysis on ALTER-0303 study[J/OL].Cancer Med,2018,7(7):3011-3021[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051165/.DOI:10.1002/cam4.1584.
[28]HAN B,LI K,WANG Q,et al.P3.03-006 efficiency of anlotinib as3rd line treatment in patients with different EGFR gene status,an exploratory subgroup analysis of ALTER0303 trial[J].J Thoracic Oncol,2017,12(11):S2275.DOI:10.1016/j.jtho.2017.09.1632.
[29]LI K,HAN B H,WANG Q M,et al.OS outcomes to anlotinib in patients(pts)with refractory NSCLC of both wild-type(WT)and mutant EGFR[J].JCO,2018,36(15_suppl):e21013.DOI:10.1200/jco.2018.36.15_suppl.e21013.
[30]HAN B,ZHAO Y,LI K,et al.P3.03-017blood samples NGS for baseline molecular signature of anotinib treated advanced NSCLCpatients in ALTER0303 trial[J].J Thoracic Oncol,2017,12(11):S2279.DOI:10.1016/j.jtho.2017.09.1643.
[31]LU J,ZHONG H,CHU T Q,et al.Role of anlotinib-induced CCL2decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy[J].Eur Respir J,2019,53(3):1801562.DOI:10.1183/13993003.01562-2018.
[32]SI X Y,ZHANG L,WANG H P,et al.Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer:Experiences in ALTER-0303[J/OL].Thorac Cancer,2019,10(3):551-556[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397894/.DOI:10.1111/1759-7714.12977.
[33]SUN W,WANG Z,CHEN R M,et al.Influences of anlotinib on cytochrome P450 enzymes in rats using a cocktail method[J/OL].Biomed Res Int,2017,2017:3619723[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758843/.DOI:10.1155/2017/3619723.